W
WAVEMAN · COMPANY
JNJ · Johnson & Johnson
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475
← ALL COMPANIES

JNJ

JOHNSON & JOHNSON
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0000200406
CONGRESS · 3FORM 144 · 6☆ WATCH
INSIDER NET · 180D
-$61.0M
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
3
FUNDS ADDED · QTR
2,280
13F, latest reported quarter
REVENUE GROWTH
+6.0%
XBRL, annual
NET MARGIN
28.5%
CONVERSIONS · 180D
9
codes C/M, not in net · $26.3M priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$61.0M over 180 days
-$61.0M over 90 days
below 95% of Pharma & Biotech
CONGRESS
3 members bought in the last year
more than 89% of Pharma & Biotech
FUNDS
2,280 funds added or opened last quarter
the highest in Pharma & Biotech
REVENUE
+6.0% year over year
more than 56% of Pharma & Biotech
MARGIN
28.5% net margin
more than 91% of Pharma & Biotech
BUYBACKS
$4.2B repurchased, FY to 2026-06-28
more than 99% of Pharma & Biotech
SHORT
1.1% of shares outstanding short · 3.0 days to cover · settled 2026-07-31
below 71% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Insiders are net sellers: -$61.0M across 5 people in 180 days.
2,280 funds added or opened positions in the latest 13F quarter, of 4,678 holders.
3 members of Congress reported buying it this year.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +57.3%
+57.3%12M
-2%+18%+37%+57%2025-092025-102025-122026-032026-052026-072026-09 2026-08-13 · Duato Joaquin sold $26.7M2026-01-26 · Duato Joaquin sold $11.3M2026-08-05 · Duato Joaquin sold $10.8M2026-01-26 · Duato Joaquin sold $10.8M2025-09-04 · Taubert Jennifer L sold $10.0M2026-02-17 · Wolk Joseph J sold $8.1M2026-02-17 · REED JOHN C sold $7.3M2026-09-02 · Schmid Timothy sold $6.2M2026-02-17 · Wolk Joseph J sold $6.1M2026-07-20 · Broadhurst Vanessa sold $5.8M2026-08-13 · Duato Joaquin sold $5.5M2026-02-13 · Swanson James D. sold $5.4M2026-02-17 · REED JOHN C sold $5.3M2026-02-17 · Swanson James D. sold $5.0M2026-02-13 · Swanson James D. sold $4.7M2026-02-17 · Wolk Joseph J sold $4.7M2025-10-17 · REED JOHN C sold $4.2M2026-08-17 · Taubert Jennifer L sold $4.0M2026-02-18 · Schmid Timothy sold $3.3M2026-09-02 · Schmid Timothy sold $3.0M2026-02-17 · Wolk Joseph J sold $2.9M2026-06-11 · Wengel Kathryn E sold $2.4M2026-08-06 · Forminard Elizabeth sold $2.4M2026-02-18 · Schmid Timothy sold $2.2M2026-08-05 · Duato Joaquin sold $1.7M2026-08-06 · Forminard Elizabeth sold $1.7M2026-02-17 · Broadhurst Vanessa sold $1.5M2026-02-27 · Decker Robert J sold $1.0M2026-02-17 · REED JOHN C sold $554.8K2026-02-20 · Schmid Timothy sold $324.8K2025-11-26 · MORIKIS JOHN G bought $257.7K2026-09-02 · Schmid Timothy filed to sell $9.2M2026-08-17 · Taubert Jennifer L filed to sell $4.0M2026-08-13 · Duato Joaquin filed to sell $32.2M2026-08-06 · Forminard Elizabeth filed to sell $4.1M2026-08-05 · Joaquin Duato filed to sell $12.4M2026-07-20 · Broadhurst Vanessa filed to sell $5.8M
INSIDER BUYINSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $61.0M sold by insiders over 180 days, 2,280 funds added last quarter, 3 Congress member(s) bought in 12 months, $67.6M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, JOHNSON & JOHNSON insiders sold a net $61.0M of stock across 251 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-04.

INSIDER
FILED
SHARES
VALUE
Schmid Timothy
EVP, WW Chair, MedTech
SELL
2026-09-02
11,070.0
$3.0M
Schmid Timothy
EVP, WW Chair, MedTech
SELL
2026-09-02
22,527.0
$6.2M
Taubert Jennifer L
EVP, WWC. Innovative Medicine
SELL
2026-08-17
15,000.0
$4.0M
Duato Joaquin
CEO and Chairman of the Board
SELL
2026-08-13
20,976.0
$5.5M
Duato Joaquin
CEO and Chairman of the Board
SELL
2026-08-13
102,315.0
$26.7M
251 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 246 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
BlackRock, Inc.
212,098,264.0 sh
$53.9B
VANGUARD CAPITAL MANAGEMENT LLC
157,226,374.0 sh
$39.9B
STATE STREET CORP
133,776,025.0 sh
$34.0B
VANGUARD PORTFOLIO MANAGEMENT LLC
64,370,816.0 sh
$16.3B
JPMORGAN CHASE & CO
58,301,609.0 sh
$15.1B
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
Schmid Timothy
FILED 2026-09-02
$9.2M
Taubert Jennifer L
FILED 2026-08-17
$4.0M
Duato Joaquin
FILED 2026-08-13
$32.2M
Forminard Elizabeth
FILED 2026-08-06
$4.1M
Joaquin Duato
FILED 2026-08-05
$12.4M
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
iShares U.S. Pharmaceuticals ETF
$230.4M POSITION · AS OF 2026-03-31
23.0%
State Street(R) Health Care Select Sector SPDR(R) ETF
$4.3B POSITION · AS OF 2026-03-31
11.1%
Health Sciences Portfolio
$39.0M POSITION · AS OF 2026-03-31
10.9%
PROFUND VP HEALTH CARE
$3.2M POSITION · AS OF 2026-03-31
10.7%
BlackRock Health Sciences Opportunities Portfolio
$667.9M POSITION · AS OF 2026-02-27
10.2%
iShares U.S. Healthcare ETF
$284.1M POSITION · AS OF 2026-04-30
10.1%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Executive pay vs shareholder return · A. Gorsky
DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself
FY
CEO TOTAL
ACTUALLY PAID
OTHER NEOs AVG
TSR
PEER TSR
2025
$32.8M
$68.3M
$12.5M
+52%
+89%
2024
$24.3M
$17.0M
$11.2M
+3%
+48%
2023
$28.4M
$13.8M
$12.5M
+8%
+37%
2022
$13.1M
$18.9M
$8.0M
+18%
+37%
2021
$26.7M
$39.4M
$12.5M
+11%
+26%
TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122023-01
REVENUE$94.2B$88.8B$85.2B$80.0B
GROSS PROFIT$63.9B$61.4B$58.6B$55.4B
NET INCOME$26.8B$14.1B$35.2B$17.9B
EPS (DILUTED)11.035.7913.726.73
OPERATING CASH FLOW$24.5B$24.3B$22.8B$21.2B
CASH$19.7B$24.1B$21.9B$12.9B
LONG-TERM DEBT$39.4B$30.7B$25.9B$26.9B
BUYBACKS$6.0B$2.4B$5.1B$6.0B
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-04 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-04 ALL SYSTEMS LIVE FOR MACHINES →